NCT06757647 - Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging of the Heart

Undergo CMR

Trial Locations (1)

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus